Malignant Bone Marrow Neoplasm

Three chronic myeloid leukemia patients had the BCR-ABL1 fusion with the E255V secondary variant in one or more bacterial clones generated using peripheral blood RNA. They had no best cytogenetic resp… (full text at CIViC)

PMID 16775234 · Talpaz et al., 2006 · Open in CIViC

In this phase II multinational study, patients with accelerated phase CML and BCR-ABL fusions were treated with dasatinib monotherapy. Response rate among 60 imatinib-resistant patients with BCR-ABL m… (full text at CIViC)

PMID 17264298 · Guilhot et al., 2007 · Open in CIViC

In an in vitro study, a Ba/F3 cell line stably expressing the E255V mutation in the ABL1 portion of the BCR-ABL1 fusion protein was found to have increased sensitivity to dasatinib treatment, as comp… (full text at CIViC)

PMID 15256671 · Shah et al., 2004 · Open in CIViC

In an in vitro study, a Ba/F3 cell line expressing an E255V mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with sensitivity to dasatinib treatment (11.0 nmol/L vs. 0.8 nmol… (full text at CIViC)

PMID 15930265 · O'Hare et al., 2005 · Open in CIViC

In an in vitro study, a Ba/F3 cell line stably expressing the E255V mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with reduced sensitivity to dasatinib treatment (IC50: 6.… (full text at CIViC)

PMID 19075254 · Redaelli et al., 2009 · Open in CIViC

In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. An AP patient had a complete hematologic respons… (full text at CIViC)

PMID 12623848 · Branford et al., 2003 · Open in CIViC

In a phase II study of 60 imatinib-resistant patients with BCR-ABL mutations, 2 had E255V mutations.

PMID 17264298 · Guilhot et al., 2007 · Open in CIViC

In a study of 39 chronic phase CML patients with BCR-ABL variants, E255V was seen in a single imatinib-resistant patient that was also resistant or intolerant to dasatinib and/or nilotinib treatment. … (full text at CIViC)

PMID 22371878 · Khoury et al., 2012 · Open in CIViC

In an in vitro study, a Ba/F3 cell line stably expressing the E255V mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to nilotinib treatment (IC50: 10.31-fold… (full text at CIViC)

PMID 19075254 · Redaelli et al., 2009 · Open in CIViC

In this open-label, phase II registration trial, patients that were imatinib resistant or intolerant underwent nilotinib monotherapy. Within 12 months of nilotinib therapy, there was no significant di… (full text at CIViC)

PMID 19652056 · Hughes et al., 2009 · Open in CIViC

In an in vitro study, a Ba/F3-p210BCR-ABL1 cell line was ENU-mutated and exposed to graded concentrations of imatinib, nilotinib or dasatinib to identify resistance mutations. The E255V mutation in th… (full text at CIViC)

PMID 16772610 · Bradeen et al., 2006 · Open in CIViC

In an in vitro study, pro-B Ba/F3 cell line expressing a compound mutant of both E255V and V299L mutations in the ABL1 portion of the BCR-ABL1 fusion protein demonstrated resistance to axitinib treatm… (full text at CIViC)

PMID 26582647 · Zabriskie et al., 2016 · Open in CIViC

In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed similar incorporation when harboring fusions with the… (full text at CIViC)

PMID 25686603 · Pemovska et al., 2015 · Open in CIViC

In an in vitro study, a Ba/F3 murine cell line stably expressing the E279K mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with sensitivity to bosutinib treatment (IC50: 39.… (full text at CIViC)

PMID 19075254 · Redaelli et al., 2009 · Open in CIViC

In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed similar incorporation when harboring fusions with the… (full text at CIViC)

PMID 25686603 · Pemovska et al., 2015 · Open in CIViC

In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC)

PMID 19779040 · Müller et al., 2009 · Open in CIViC

In an in vitro study, a Ba/F3-p210BCR-ABL1 cell line was ENU-mutated and exposed to graded concentrations of imatinib, nilotinib or dasatinib. The E292V mutation in the ABL1 portion of the BCR-ABL1 fu… (full text at CIViC)

PMID 16772610 · Bradeen et al., 2006 · Open in CIViC

In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and ma… (full text at CIViC)

PMID 21865346 · Cortes et al., 2011 · Open in CIViC

This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from … (full text at CIViC)

PMID 19779040 · Müller et al., 2009 · Open in CIViC

Prior to dasatinib treatment, one imatinib-resistant patient with chronic myeloid leukemia in chronic phase had the BCR-ABL1 fusion with E450Q/M351T and E450Q variants in 1/10 and 9/10 clones, respect… (full text at CIViC)

PMID 16775234 · Talpaz et al., 2006 · Open in CIViC

In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and ma… (full text at CIViC)

PMID 21865346 · Cortes et al., 2011 · Open in CIViC

In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC)

PMID 19779040 · Müller et al., 2009 · Open in CIViC

This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chro… (full text at CIViC)

PMID 22371878 · Khoury et al., 2012 · Open in CIViC

In a study of 39 chronic phase CML patients with BCR-ABL variants, E453A was seen in a single imatinib-resistant patient that was also resistant or intolerant to dasatinib and/or nilotinib treatment. … (full text at CIViC)

PMID 22371878 · Khoury et al., 2012 · Open in CIViC

In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and ma… (full text at CIViC)

PMID 21865346 · Cortes et al., 2011 · Open in CIViC

In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC)

PMID 19779040 · Müller et al., 2009 · Open in CIViC

In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and ma… (full text at CIViC)

PMID 21865346 · Cortes et al., 2011 · Open in CIViC

This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from … (full text at CIViC)

PMID 19779040 · Müller et al., 2009 · Open in CIViC

In this phase II multinational study, patients with accelerated phase CML and BCR-ABL fusions were treated with dasatinib monotherapy. Response rate among 60 imatinib-resistant patients with BCR-ABL m… (full text at CIViC)

PMID 17264298 · Guilhot et al., 2007 · Open in CIViC

Prior to dasatinib treatment, one imatinib-resistant patient with chronic myeloid leukemia in chronic phase had the BCR-ABL1 fusion with the E98G secondary variant in 11/11 bacterial clones generated … (full text at CIViC)

PMID 16775234 · Talpaz et al., 2006 · Open in CIViC

One chronic myeloid leukemia patient in chronic phase had a complete best cytogenetic response to imatinib but became resistant. Bacterial clones generated using peripheral blood RNA later revealed th… (full text at CIViC)

PMID 16775234 · Talpaz et al., 2006 · Open in CIViC

In an in vitro study, pro-B Ba/F3 cell line expressing F311I mutation in the ABL1 portion of the BCR-ABL1 fusion protein (overexpression) demonstrated resistance to axitinib treatment (IC50: 935.6nM),… (full text at CIViC)

PMID 26582647 · Zabriskie et al., 2016 · Open in CIViC

In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and ma… (full text at CIViC)

PMID 21865346 · Cortes et al., 2011 · Open in CIViC

In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and ma… (full text at CIViC)

PMID 21865346 · Cortes et al., 2011 · Open in CIViC

In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC)

PMID 19779040 · Müller et al., 2009 · Open in CIViC